Vaccine-associated thrombocytopenia

Area of Science:

• Immunology
• Vaccinology
• Hematology

Background:

• Vaccination is crucial for preventing infectious diseases, but adverse reactions can occur.
• Rarely, serious adverse events like immune thrombocytopenia (ITP) are reported post-vaccination.
• The measles-mumps-rubella (MMR) vaccine is linked to ITP, primarily in children.

Purpose of the Study:

• To review vaccine-associated immune thrombocytopenia (ITP).
• To discuss the incidence and characteristics of ITP following MMR and COVID-19 vaccination.
• To outline current treatment approaches for vaccine-associated ITP.

Main Methods:

• Literature review of vaccine-associated immune thrombocytopenia (ITP).
• Analysis of reported cases and incidence rates for MMR and COVID-19 vaccine-associated ITP.
• Summary of established treatment protocols for ITP.

Main Results:

• The measles-mumps-rubella (MMR) vaccine has a demonstrated causal link to ITP (0.087-4 per 100,000 doses), mainly in children.
• COVID-19 vaccines can also induce thrombocytopenia, typically within weeks post-vaccination, predominantly in the elderly.
• Patients with pre-existing chronic ITP, especially those post-splenectomy or on multiple medications, may experience exacerbation after COVID-19 vaccination.

Conclusions:

• Vaccine-associated immune thrombocytopenia (ITP) is a rare but recognized adverse event.
• Treatment strategies for vaccine-induced ITP mirror those for primary ITP, including glucocorticoids and intravenous immunoglobulin (IVIg).
• Further research may be needed to fully understand and manage vaccine-associated ITP, particularly in vulnerable populations.